Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis

References

• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi:10.1016/S0140-6736(14)61909-7
   PubMed Web of Science ®Google Scholar
• WHO. World psoriasis day-document EB133.R2, agenda item 6.2. 2013. https://apps.who.int/gb/ebwha/pdf_files/EB133/B133_R2-en.pdf. Accessed May 14, 2020
   Google Scholar
• Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3):401–407. doi:10.1016/S0190-9622(99)70112-X
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Mechanisms of disease: psoriasis. N Engl J Med. 2009;361(5):5. doi:10.1056/NEJMra0804595
   Web of Science ®Google Scholar
• Boehncke WH. Etiology and Pathogenesis of Psoriasis. Rheum Dis Clin North Am. 2015;41(4):665–675. doi:10.1016/j.rdc.2015.07.013
   PubMed Web of Science ®Google Scholar
• Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20(6):6. doi:10.3390/ijms20061475
   Web of Science ®Google Scholar
• Gunter NV, Yap BJM, Chua CLL, Yap WH. Combining Understanding of Immunological Mechanisms and Genetic Variants Toward Development of Personalized Medicine for Psoriasis Patients. Front Genet. 2019;10:(MAY):395. doi:10.3389/fgene.2019.00395
   PubMed Web of Science ®Google Scholar
• Finlay AY. Current severe psoriasis and the Rule of Tens. Br J Dermatol. 2005;152(5):861–867. doi:10.1111/j.1365-2133.2005.06502.x
   PubMed Web of Science ®Google Scholar
• Gordon KB, Reich K, Crowley JJ, et al. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab Phase 3 clinical trials. J Dermatolog Treat. 2020:1–10. doi:10.1080/09546634.2020.1747590
   Web of Science ®Google Scholar
• Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C. Absolute and relative psoriasis area and severity indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis: an integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes. Acta Derm Venereol. 2019;99(11):971–977. doi:10.2340/00015555-3245
   PubMed Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1:CD011535. doi:10.1002/14651858.CD011535.pub3
   PubMed Web of Science ®Google Scholar
• Kim HJ, Lebwohl MG. Biologics and Psoriasis: the Beat Goes On. Dermatol Clin. 2019;37(1):29–36. doi:10.1016/j.det.2018.07.004
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. ILUMYA (tildrakizumab-asmn).2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf. Accessed August 27, 2020.
   Google Scholar
• Ilumetri | European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri. Accessed June 18, 2020.
   Google Scholar
• Khalilieh S, Hodsman P, Xu C, Tzontcheva A, Glasgow S, Montgomery D. Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects. Basic Clin Pharmacol Toxicol. 2018;123(3):294–300. doi:10.1111/bcpt.13001
   PubMed Web of Science ®Google Scholar
• Kopp T, Riedl E, Bangert C, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature. 2015;521(7551):222–226. doi:10.1038/nature14175
   PubMed Web of Science ®Google Scholar
• Khalilieh S, Hussain A, Montgomery D, et al. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis. Br J Clin Pharmacol. 2018;84(10):2292–2302. doi:10.1111/bcp.13670
   PubMed Web of Science ®Google Scholar
• Zandvliet A, Glasgow S, Horowitz A, et al. Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects. Int J Clin Pharmacol Ther. 2015;53(2):139–146. doi:10.5414/CP202176
   PubMed Web of Science ®Google Scholar
• Jauslin P, Kulkarni P, Li H, et al. Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis. Clin Pharmacokinet. 2019;58(8):1059–1068. doi:10.1007/s40262-019-00743-7
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. TREMFYA ® (guselkumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf. Accessed June 18, 2020.
   Google Scholar
• US Food and Drug Administration. SKYRIZI ® (risankizumab-rzaa). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf. Accessed June 18, 2020.
   Google Scholar
• US Food and Drug Administration. CENTER FOR DRUG EVALUATION AND RESEARCH. ILUMYA (Tildrakizumab). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761067Orig1s000MultdisciplineR.pdf. Accessed June 22, 2020.
   Google Scholar
• US Food and Drug Administration. CENTER FOR DRUG EVALUATION AND RESEARCH. TREMFYA (Guselkumab). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761061Orig1s000MultidisciplineR.pdf. Accessed June 22, 2020.
   Google Scholar
• Therapeutic Goods Administration. Australian Public Assessment Report for Risankizumab.; 2020. Accessed June 22, 2020. https://www.tga.gov.au/sites/default/files/auspar-risankizumab-200122.pdf.
   Google Scholar
• Papp K, Thaçi D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930–939. doi:10.1111/bjd.13932
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288. doi:10.1016/S0140-6736(17)31279-5
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605–617. doi:10.1111/bjd.18232
   PubMed Web of Science ®Google Scholar
• Poulin Y, Ramon M, Rosoph L, et al. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis. J Eur Acad Dermatology Venereol. 2020:jdv.16187. doi:10.1111/jdv.16187
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Blauvelt A, et al. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. J Eur Acad Dermatology Venereol. 2019;33(6):1098–1106. doi:10.1111/jdv.15400
   PubMed Web of Science ®Google Scholar
• Kerbusch T, Li H, Wada R, Jauslin PM, Wenning L. Exposure–response characterisation of tildrakizumab in chronic plaque psoriasis: pooled analysis of 3 randomised controlled trials. Br J Clin Pharmacol. 2020;86(9):1795–1806. doi:10.1111/bcp.14280
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Sofen H, Papp K, et al. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatology Venereol. 2019;33(12):2305–2312. doi:10.1111/jdv.15862
   PubMed Web of Science ®Google Scholar
• Kimball AB, Papp KA, Reich K, et al. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. Br J Dermatol. 2019;182(4):6. doi:10.1111/bjd.18484
   Web of Science ®Google Scholar
• Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Bin RI, Kurtzman DJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat. 2018;29(6):569–578. doi:10.1080/09546634.2017.1422591
   PubMed Web of Science ®Google Scholar
• Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS One. 2019;14(8):8. doi:10.1371/journal.pone.0220868
   Web of Science ®Google Scholar
• Armstrong AW, Puig L, Joshi A, et al. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatology. 2020;156(3):258–269. doi:10.1001/jamadermatol.2019.4029
   PubMed Web of Science ®Google Scholar
• Xu S, Zhang X, Pan M, Shuai Z, Xu S, Pan F. Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis. Int Immunopharmacol. 2019;75. doi:10.1016/j.intimp.2019.105841
   Web of Science ®Google Scholar
• Reich K, Griffiths CEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936–945. doi:10.1016/j.jaad.2019.11.040
   PubMed Web of Science ®Google Scholar
• Reddy V, Yang EJ, Myers B, Liao W. Clinical evaluation of risankizumab-rzaa in the treatment of plaque psoriasis. J Inflamm Res. 2020;13:53–60. doi:10.2147/JIR.S215196
   PubMed Web of Science ®Google Scholar
• AbbVie. A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS). https://clinicaltrials.gov/ct2/show/NCT03047395. Accessed June 16, 2020.
   Google Scholar
• Langley RG, Papp K, Gottlieb AB, et al. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatology Venereol. 2013;27(10):1252–1261. doi:10.1111/j.1468-3083.2012.04705.x
   PubMed Web of Science ®Google Scholar
• Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177(1):47–62. doi:10.1111/bjd.15015
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81–89.e5. doi:10.1016/j.jaad.2017.08.024
   PubMed Web of Science ®Google Scholar
• Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatology Venereol. 2019;33(9):1676–1684. doi:10.1111/jdv.15653
   PubMed Web of Science ®Google Scholar
• Xu S, Zhang X, Pan M, Shuai Z, Xu S, Pan F. Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis. Int Immunopharmacol. 2019;75:105841. doi:10.1016/j.intimp.2019.105841
   PubMed Web of Science ®Google Scholar
• Jullien D, Prinz JC, Nestle FO. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. J Invest Dermatol. 2015;135(1):31–38. doi:10.1038/jid.2014.295
   PubMed Web of Science ®Google Scholar
• Pratt K. Anti-Drug Antibodies: emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity. Antibodies. 2018;7(2):19. doi:10.3390/antib7020019
   Web of Science ®Google Scholar
• Kimball AB, Kerbusch T, van Aarle F, et al. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. Br J Dermatol. 2020;182(1):180–189. doi:10.1111/bjd.17918
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. COSENTYX ® (secukinumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125504s013lbl.pdf. Accessed June 19, 2020.
   Google Scholar
• US Food and Drug Administration. TALTZ (ixekizumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125521s004lbl.pdf. Accessed June 19, 2020.
   Google Scholar
• US Food and Drug Administration. SILIQ (brodalumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf. Accessed June 19, 2020.
   Google Scholar
• US Food and Drug Administration. STELARA ® (ustekinumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125261s147lbl.pdf. Accessed June 19, 2020.
   Google Scholar
• Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatology Venereol. 2011;25(9):1007–1011. doi:10.1111/j.1468-3083.2011.04065.x
   PubMed Web of Science ®Google Scholar